TY - JOUR
T1 - Interfacing engineered nanoparticles with biological systems
T2 - Anticipating adverse nano-bio interactions
AU - Pelaz, Beatriz
AU - Charron, Gaëlle
AU - Pfeiffer, Christian
AU - Zhao, Yuliang
AU - De La Fuente, Jesus M.
AU - Liang, Xing Jie
AU - Parak, Wolfgang J.
AU - Del Pino, Pablo
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/5/27
Y1 - 2013/5/27
N2 - The innovative use of engineered nanomaterials in medicine, be it in therapy or diagnosis, is growing dramatically. This is motivated by the current extraordinary control over the synthesis of complex nanomaterials with a variety of biological functions (e.g. contrast agents, drug-delivery systems, transducers, amplifiers, etc.). Engineered nanomaterials are found in the bio-context with a variety of applications in fields such as sensing, imaging, therapy or diagnosis. As the degree of control to fabricate customized novel and/or enhanced nanomaterials evolves, often new applications, devices with enhanced performance or unprecedented sensing limits can be achieved. Of course, interfacing any novel material with biological systems has to be critically analyzed as many undesirable adverse effects can be triggered (e.g. toxicity, allergy, genotoxicity, etc.) and/or the performance of the nanomaterial can be compromised due to the unexpected phenomena in physiological environments (e.g. corrosion, aggregation, unspecific absorption of biomolecules, etc.). Despite the need for standard protocols for assessing the toxicity and bio-performance of each new functional nanomaterial, these are still scarce or currently under development. Nonetheless, nanotoxicology and relating adverse effects to the physico-chemical properties of nanomaterials are emerging areas of the utmost importance which have to be continuously revisited as any new material emerges. This review highlights recent progress concerning the interaction of nanomaterials with biological systems and following adverse effects. The biological fate of engineered nanoparticles (NPs) in physiological media is discussed. The four color-labeled scenarios illustrate (green) potential adverse effects following protein adsorption, (orange) functionalization of NPs with cell-penetrating peptides (CPPs) and antibodies (active targeting), (yellow) the possibility of 'passivating' NPs with suitable coatings, (blue) and adverse effects such as 'NP dissolution' and reactive oxygen species generation.
AB - The innovative use of engineered nanomaterials in medicine, be it in therapy or diagnosis, is growing dramatically. This is motivated by the current extraordinary control over the synthesis of complex nanomaterials with a variety of biological functions (e.g. contrast agents, drug-delivery systems, transducers, amplifiers, etc.). Engineered nanomaterials are found in the bio-context with a variety of applications in fields such as sensing, imaging, therapy or diagnosis. As the degree of control to fabricate customized novel and/or enhanced nanomaterials evolves, often new applications, devices with enhanced performance or unprecedented sensing limits can be achieved. Of course, interfacing any novel material with biological systems has to be critically analyzed as many undesirable adverse effects can be triggered (e.g. toxicity, allergy, genotoxicity, etc.) and/or the performance of the nanomaterial can be compromised due to the unexpected phenomena in physiological environments (e.g. corrosion, aggregation, unspecific absorption of biomolecules, etc.). Despite the need for standard protocols for assessing the toxicity and bio-performance of each new functional nanomaterial, these are still scarce or currently under development. Nonetheless, nanotoxicology and relating adverse effects to the physico-chemical properties of nanomaterials are emerging areas of the utmost importance which have to be continuously revisited as any new material emerges. This review highlights recent progress concerning the interaction of nanomaterials with biological systems and following adverse effects. The biological fate of engineered nanoparticles (NPs) in physiological media is discussed. The four color-labeled scenarios illustrate (green) potential adverse effects following protein adsorption, (orange) functionalization of NPs with cell-penetrating peptides (CPPs) and antibodies (active targeting), (yellow) the possibility of 'passivating' NPs with suitable coatings, (blue) and adverse effects such as 'NP dissolution' and reactive oxygen species generation.
KW - active/passive targeting
KW - anti-fouling coatings
KW - opsonization
KW - protein adsorption
KW - ROS generation
UR - http://www.scopus.com/inward/record.url?scp=84878103207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878103207&partnerID=8YFLogxK
U2 - 10.1002/smll.201201229
DO - 10.1002/smll.201201229
M3 - Review article
C2 - 23112130
AN - SCOPUS:84878103207
SN - 1613-6810
VL - 9
SP - 1573
EP - 1584
JO - Small
JF - Small
IS - 9-10
ER -